| Autor: |
Yufan, Huang, Maojin, You, Qingfeng, Wu, Wei, Zhu, Fei, Guo, Wangchun, Lin |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Annals of clinical and laboratory science. 52(6) |
| ISSN: |
1550-8080 |
| Popis: |
Shc SH2 domain-binding protein (SHCBP1) is involved in regulating tumour progression in a variety of tumour types. The aim of this study was to analyze the prognostic landscape of SHCBP1 in pan-cancer and investigate the relationship between SHCBP1 expression and tumour immune microenvironment.The Cancer Genome Atlas (TCGA) and genotype tissue expression (GTEx) database were used for obtaining the required data for the evaluation of SHCBP1 expression. The clinical characteristics and prognostic role of SHCBP1 were analyzed by using TCGA cohort. This was followed by gene set enrichment analysis by R software. Based on TCGA pan-cancer data, the correlation between SHCBP1 expression and immune infiltration, immune-related genes, microsatellite instability (MSI), and tumour mutational burden (TMB) was discussed. Finally, the half-maximum inhibitory concentration (ICSHCBP1 was upregulated in most tumours showing a significant association with poor prognosis. Gene set enrichment analysis revealed SHCBP1 relation to the immunity, cell cycle, and cancer pathway in various types of tumour. SHCBP1 expression also showed a positive correlation with tumour-associated macrophages (TAMs) and immunosuppressive genes including TGFBR1, PD-L1 and TGFB1 and so on. In addition, high expression of SHCBP1 in patients was associated with resistance to a variety of anti-tumour drugs.The present study confirms SHCBP1 as a poor prognostic marker of cancers. Its high expression is suggested to be involved in immunological resistance to a variety of anti-tumour drugs. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
